AEMD

Aethlon Medical, Inc. (AEMD) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Aethlon Medical, Inc. is a clinical-stage medical therapeutic company developing the Hemopurifier® (HP), a device designated as a "Breakthrough Device" by the FDA for treating advanced cancer and life-threatening viral infections. The company operates as a single segment focused on advancing clinical trials and pre-clinical research. As of November 10, 2025, the company had 761,318 shares of common stock outstanding.

Key Financial Metrics

Note: The company has no commercial revenue. Operating expenses include Research & Development (R&D) costs embedded within payroll, professional fees, and general and administrative lines.

Material Changes vs. Prior Period

• Expense Reduction: Operating expenses decreased by approximately 48% ($1.39 million) for the three months ended September 30, 2025, compared to the same period in 2024. This was driven by a $778,000 reduction in payroll (excluding prior-year severance charges) and lower general and administrative costs.
• Net Loss Improvement: Net loss decreased to $1.49 million for the quarter from $2.81 million in the prior year quarter, primarily due to reduced operating expenses.
• Capital Raise: In September 2025, the company completed a registered direct offering, raising approximately $3.7 million in net proceeds. This contrasts with the prior year period where financing activities were more robust ($5.38 million net).
• Tax Incentive: The company recognized an Australian Research and Development Tax Incentive of approximately $218,000, which reduced reported R&D expenses for the period.

Outlook, Risks, and Management Commentary

• Clinical Progress: The Phase 1 oncology trial in Australia is ongoing. The Data Safety Monitoring Board (DSMB) reviewed the first cohort (3 participants) and found no safety concerns. Enrollment for Cohort 2 is open. The company cancelled a planned trial in India to conserve resources and focus on the Australian study.
• Liquidity and Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Existing cash as of September 30, 2025, is not expected to fund operations for at least twelve months. The company is actively evaluating financing options, including equity offerings.
• Stock Split: A 1-for-10 reverse stock split was implemented on October 16, 2025, to address Nasdaq minimum bid price requirements. Financial statements have been retroactively adjusted to reflect this split.
• Regulatory Risks: The company faces risks related to the U.S. government shutdown (beginning October 1, 2025), which may delay FDA reviews and regulatory approvals. Additionally, the company must secure additional capital to sustain operations and clinical trials.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.85 million cash balance against projected burn rates, given the explicit "substantial doubt" regarding going concern status.
• Financing Terms: Review the terms of the September 2025 registered direct offering, including the exercise price of warrants ($0.90) and potential dilution from the 5 million warrants issued.
• Clinical Milestones: Monitor the safety and feasibility data from Cohort 2 of the Australian oncology trial and the timeline for potential expansion.
• Regulatory Status: Track the impact of the U.S. government shutdown on FDA review timelines and the status of the manufacturing supplement approval for the San Diego facility.
• Reverse Split Impact: Confirm the post-split trading volume and compliance with Nasdaq listing requirements following the October 2025 split.